HomeCompareALPMF vs SPHD

ALPMF vs SPHD: Dividend Comparison 2026

ALPMF yields 3.14% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALPMF wins by $25.97M in total portfolio value
10 years
ALPMF
ALPMF
● Live price
3.14%
Share price
$16.15
Annual div
$0.51
5Y div CAGR
83.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.00M
Annual income
$22,649,486.27
Full ALPMF calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — ALPMF vs SPHD

📍 ALPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPMFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPMF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPMF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPMF
Annual income on $10K today (after 15% tax)
$267.05/yr
After 10yr DRIP, annual income (after tax)
$19,252,063.33/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, ALPMF beats the other by $19,251,577.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPMF + SPHD for your $10,000?

ALPMF: 50%SPHD: 50%
100% SPHD50/50100% ALPMF
Portfolio after 10yr
$13.01M
Annual income
$11,325,028.79/yr
Blended yield
87.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPMF buys
0
SPHD buys
0
No recent congressional trades found for ALPMF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPMFSPHD
Forward yield3.14%4.33%
Annual dividend / share$0.51$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83.1%0%
Portfolio after 10y$26.00M$26.5K
Annual income after 10y$22,649,486.27$571.32
Total dividends collected$25.70M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ALPMF vs SPHD ($10,000, DRIP)

YearALPMF PortfolioALPMF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$11,275$575.25$11,133$432.85+$142.00ALPMF
2$13,174$1,109.91$12,363$450.36+$811.00ALPMF
3$16,316$2,219.21$13,695$467.39+$2.6KALPMF
4$22,161$4,703.07$15,138$483.90+$7.0KALPMF
5$34,643$10,931.15$16,697$499.88+$17.9KALPMF
6$66,310$29,241.64$18,382$515.31+$47.9KALPMF
7$166,730$95,777.84$20,198$530.17+$146.5KALPMF
8$590,501$412,100.01$22,157$544.46+$568.3KALPMF
9$3,129,389$2,497,553.06$24,266$558.18+$3.11MALPMF
10$25,997,932$22,649,486.27$26,536$571.32+$25.97MALPMF

ALPMF vs SPHD: Complete Analysis 2026

ALPMFStock

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Full ALPMF Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ALPMF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPMF vs SCHDALPMF vs JEPIALPMF vs OALPMF vs KOALPMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.